Abstract
Morphine antinociception has been shown to be influenced significantly by genetic factors, now beginning to be identified in mice. A recent quantitative trait locus analysis revealed a significant statistical association between morphine antinociceptive magnitude and a region of mouse chromosome 9. This region contains theHtr1b gene, which encodes the 5-hydroxytryptamine (serotonin)-1B (5-HT1B) receptor subtype. To investigate the possibility that Htr1b represents the quantitative trait locus, C57BL/6 and DBA/2 inbred strains, the progenitors of the original quantitative trait locus mapping populations, were administered a novel 5-HT1B receptor antagonist (GR127935) concomitant with morphine. These mice are known to differ in morphine antinociceptive sensitivity on thermal pain assays (DBA/2 high; C57BL/6 low). GR127935 caused a dose-dependent antagonism (both reversal and prevention) of morphine antinociception in DBA/2 mice but had no effect in C57BL/6 mice. However, a 5-hydroxytryptamine-1A subtype (5-HT1A) receptor agonist, 8-hydroxydipropylaminotetralin, reversed morphine antinociception equally in the two strains. DBA/2 mice also exhibited significantly greater antinociception than did C57BL/6 mice from the administration of a 5-HT1B agonist, CGS12066. These data collectively support a role for 5-HT1Breceptors in the mediation of morphine antinociception and support the contention that polymorphisms in the Htr1b gene may underlie individual differences in morphine sensitivity.
Footnotes
-
Send reprint requests to: Heather Hain, Dept. of Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research, 2800 Plymouth Ave., Ann Arbor, MI 48105. E-mail:heather.hain{at}wl.com
-
↵1 This work was supported by National Institute on Drug Abuse Grants T32DA07262 (H.S.H.) and DA11394 (J.S.M.), and a Veterans Affairs Merit Review Project (J.K.B.).
- Abbreviations:
- RI
- recombinant inbred
- QTL
- quantitative trait locus
- 5-HT1B
- 5-hydroxytryptamine (serotonin)-1B subtype
- 5-HT1A
- 5-hydroxytryptamine 1A subtype
- 8-OH-DPAT
- 8-hydroxydipropylaminotetralin
- %MPE
- percentage of the maximum possible effect
- AUC
- area under the curve
- AD50
- half-maximal antinociceptive dose
- Received October 29, 1998.
- Accepted April 8, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|